Page last updated: 2024-12-07

carboxyatractyloside

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

carboxyatractyloside: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101834999
MeSH IDM0044964

Synonyms (12)

Synonym
einecs 251-444-9
potassium carboxyatractyloside
cat dipotassium salt
kaur-16-ene-18,19-dioic acid, 15-hydroxy-2-((2-o-(3-methyl-1-oxobutyl)-3,4-di-o-sulfo-beta-d-glucopyranosyl)oxy)-, dipotassium salt, (2-beta,15-alpha)-
gummiferin
dipotassium carboxyatractyloside
carboxyatractyloside
snp1xl23e6 ,
unii-snp1xl23e6
33286-30-5
carboxyatractyloside dipotassium salt
dipotassium;(1r,4s,7s,9s,10s,13r,15s)-15-hydroxy-7-[(2r,3r,4r,5r,6r)-6-(hydroxymethyl)-3-(3-methylbutanoyloxy)-4,5-disulfooxyoxan-2-yl]oxy-9-methyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5,5-dicarboxylate

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The present investigation was carried out to evaluate the toxic effects on acute liver injury in mice of the two kaurene glycosides (atractyloside and carbxyatractyloside), which are main toxic constituents isolated from Fructus Xanthii on acute liver injury in mice."( Hepatotoxicity of kaurene glycosides from Xanthium strumarium L. fruits in mice.
Han, P; Han, T; Huang, BK; Ming, QL; Peng, W; Qin, LP; Wang, Y; Xue, LM; Zhang, H; Zhang, QY, 2011
)
0.37

Pharmacokinetics

ExcerptReferenceRelevance
" However, their pharmacokinetic study is lacking."( Simultaneous quantification of atractyloside and carboxyatractyloside in rat plasma by LC-MS/MS: Application to a pharmacokinetic study after oral administration of Xanthii Fructus extract.
Pan, H; Shi, F; Xiang, D; Yang, F, 2020
)
0.56

Dosage Studied

ExcerptRelevanceReference
" The percentage of competent carrier protein in liposomes was calculated from dose-response data concerning the inhibition of ADP/ATP transport by atractyloside or carboxyatractyloside, and from the amount of bound [3H]-atractyloside removable by ADP."( Kinetic, binding and ultrastructural properties of the beef heart adenine nucleotide carrier protein after incorporation into phospholipid vesicles.
Brandolin, G; Doussiere, J; Gulik, A; Gulik-Krzywicki, T; Lauquin, GJ; Vignais, PV, 1980
)
0.26
" The rats were then given a calculated LD50 dosage (13."( Toxicologic study of carboxyatractyloside (active principle in cocklebur--Xanthium strumarium) in rats treated with enzyme inducers and inhibitors and glutathione precursor and depletor.
Clark, JD; Hatch, RC; Jain, AV; Weiss, R, 1982
)
0.26
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (255)

TimeframeStudies, This Drug (%)All Drugs %
pre-199078 (30.59)18.7374
1990's95 (37.25)18.2507
2000's54 (21.18)29.6817
2010's24 (9.41)24.3611
2020's4 (1.57)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (2.30%)6.00%
Case Studies3 (1.15%)4.05%
Observational0 (0.00%)0.25%
Other252 (96.55%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]